长效HIV融合抑制剂阿巴卡韦与利托那韦增强的洛匹那韦联合用于一线抗逆转录病毒治疗失败后的HIV-1感染患者：48周随机、对照、3期非劣效性TALENT研究 - Suppr

Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study.

作者信息

Su Bin, Yao Cheng, Zhao Qing-Xia, Cai Wei-Ping, Wang Min, Lu Hong-Zhou, Mu Ting-Ting, Chen Yuan-Yuan, Liu Li, Wang Hui, He Yun, Zheng Yu-Huang, Li Ling-Hua, Chen Jin-Feng, Yu Jian-Hua, Zhu Biao, Zhao Min, Sun Yong-Tao, Lun Wen-Hui, Zhang Yi-Hang, Wang Hu, Xia Wei, Sun Li-Jun, Dai Li-Li, Jiang Tai-Yi, Wang Mei-Xia, Zheng Qing-Shan, Peng Hai-Yan, Wang Yao, Hu Min, Liu Xia, Lu Rong-Jian, Hu Jian-Hua, Sun Cheng-Chen, Xing Hui, Shao Yi-Ming, Xie Dong, Zhang Tong, Zhang Fu-Jie, Wu Hao

机构信息

Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.

Frontier Biotechnologies Inc., Nanjing, Jiangsu 211122, China.

出版信息

J Infect. 2022 Sep;85(3):334-363. doi: 10.1016/j.jinf.2022.05.034. Epub 2022 Jun 1.

DOI:10.1016/j.jinf.2022.05.034

PMID:35659547

Abstract

摘要

相似文献

Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study.长效HIV融合抑制剂阿巴卡韦与利托那韦增强的洛匹那韦联合用于一线抗逆转录病毒治疗失败后的HIV-1感染患者：48周随机、对照、3期非劣效性TALENT研究

J Infect. 2022 Sep;85(3):334-363. doi: 10.1016/j.jinf.2022.05.034. Epub 2022 Jun 1.

Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study.长效融合抑制剂 albuvirtide 在抗逆转录病毒治疗经验丰富的成人 HIV-1 感染者中的疗效和安全性：随机、对照、III 期非劣效性 TALENT 研究的中期分析。

Chin Med J (Engl). 2020 Nov 25;133(24):2919-2927. doi: 10.1097/CM9.0000000000001273.

Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients.长效HIV融合抑制剂阿巴卡韦与洛匹那韦/利托那韦联合使用在HIV-1患者中显示出强效疗效。

AIDS Res Ther. 2016 Feb 10;13:8. doi: 10.1186/s12981-016-0091-1. eCollection 2016.

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.替拉那韦/利托那韦（500/200毫克和500/100毫克）在初治的HIV-1感染患者中，第48周时病毒学疗效不劣于洛匹那韦/利托那韦（400/100毫克）：一项随机、多国、多中心试验。

PLoS One. 2016 Jan 5;11(1):e0144917. doi: 10.1371/journal.pone.0144917. eCollection 2016.

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.在未接受过抗逆转录病毒治疗的 HIV-1 感染成人中，洛匹那韦和利托那韦联合拉米夫定双药治疗与洛匹那韦和利托那韦联合两种核苷类逆转录酶抑制剂三联治疗的随机、开放标签、非劣效性 GARDEL 试验的 48 周结果。

Lancet Infect Dis. 2014 Jul;14(7):572-80. doi: 10.1016/S1473-3099(14)70736-4. Epub 2014 Apr 27.

Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.在初治抗逆转录病毒治疗受试者中比较洛匹那韦/利托那韦与拉替拉韦以及洛匹那韦/利托那韦与替诺福韦/恩曲他滨的非劣效性、安全性和耐受性：进展研究，48周结果

HIV Clin Trials. 2011 Sep-Oct;12(5):255-67. doi: 10.1310/hct1205-255.

Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.在标准一线抗逆转录病毒治疗方案失败的 HIV 患者中，经过 96 周利托那韦增强洛匹那韦加核苷或核苷酸逆转录酶抑制剂或拉替拉韦治疗后的身体成分和代谢结果：一项随机、开放标签、非劣效性 SECOND-LINE 研究的子研究。

Lancet HIV. 2017 Jan;4(1):e13-e20. doi: 10.1016/S2352-3018(16)30189-8. Epub 2016 Nov 1.

Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir/ritonavir, in HIV-infected subjects, combined with clinical study and simulation results.在HIV感染受试者中评估长效HIV-1融合抑制剂阿巴卡韦与洛匹那韦/利托那韦之间的药代动力学相互作用，并结合临床研究和模拟结果。

Xenobiotica. 2017 Feb;47(2):133-143. doi: 10.3109/00498254.2016.1166532. Epub 2016 Apr 6.

Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.从洛匹那韦/利托那韦转换为增强和非增强型阿扎那韦对糖代谢的影响：阿扎那韦与糖代谢（ATAGLU）研究

Int J STD AIDS. 2016 Jul;27(8):638-43. doi: 10.1177/0956462415590724. Epub 2015 Jun 10.

[Positioning of lopinavir/ritonavir in antiretroviral treatment schemes].[洛匹那韦/利托那韦在抗逆转录病毒治疗方案中的定位]

Enferm Infecc Microbiol Clin. 2014 Nov;32 Suppl 3:31-4. doi: 10.1016/S0213-005X(14)70166-1.

引用本文的文献

Therapeutic efficacy of albuvirtide-based antiretroviral therapy in people living with HIV who have low-level viremia and non-AIDS-defining malignancies: two case reports.基于阿巴卡韦的抗逆转录病毒疗法对低病毒血症且无艾滋病定义恶性肿瘤的HIV感染者的治疗效果：两例病例报告

Retrovirology. 2025 Apr 18;22(1):6. doi: 10.1186/s12977-025-00662-5.

Efforts toward achieving the goal of ending AIDS by 2030: from antiretroviral drugs to HIV vaccine and cure research.为实现到2030年终结艾滋病目标所做的努力：从抗逆转录病毒药物到艾滋病毒疫苗及治愈研究

Sci China Life Sci. 2025 Jun;68(6):1849-1851. doi: 10.1007/s11427-024-2840-4. Epub 2025 Mar 4.

Enhanced immune reconstitution with albuvirtide in HIV-infected immunological non-responders.在 HIV 感染免疫无应答者中，使用 albuvirtide 增强免疫重建。

Front Cell Infect Microbiol. 2024 Jun 21;14:1397743. doi: 10.3389/fcimb.2024.1397743. eCollection 2024.

Analysis of the efficacy of drilling decompression autologous bone marrow and allogeneic bone grafting in the treatment of HIV-positive patients with early osteonecrosis of the femoral head.分析钻孔减压自体骨髓和同种异体骨移植治疗 HIV 阳性早期股骨头坏死患者的疗效。

BMC Musculoskelet Disord. 2023 Nov 21;24(1):902. doi: 10.1186/s12891-023-07039-9.

Antiviral Activity of Anthranilamide Peptidomimetics against Herpes Simplex Virus 1 and a Coronavirus.邻氨基苯甲酰胺肽模拟物对单纯疱疹病毒1型和一种冠状病毒的抗病毒活性

Antibiotics (Basel). 2023 Sep 12;12(9):1436. doi: 10.3390/antibiotics12091436.

Rescue therapy with an albuvirtide-based antiretroviral regimen in an HIV-infected child with multidrug resistance and multiple opportunistic infections: a case report.基于 albuvirtide 的抗逆转录病毒方案治疗 HIV 感染合并多种耐药和多种机会性感染儿童：病例报告。

AIDS Res Ther. 2023 Aug 28;20(1):60. doi: 10.1186/s12981-023-00560-w.

Comparison of pharmacokinetics and safety of albuvirtide in healthy subjects after intravenous drip and bolus injection.静脉滴注和推注给药后健康受试者中阿巴韦肽的药代动力学和安全性比较。

Naunyn Schmiedebergs Arch Pharmacol. 2024 Feb;397(2):913-922. doi: 10.1007/s00210-023-02614-2. Epub 2023 Aug 3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献